Dec 15, 2020 / 01:00PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Palatin PL-9643 Phase II Dry Eye Disease Clinical Trial Results Call. Before we begin our remarks, I would like to remind you that statements made by Palatin that are not historical facts may be forward-looking statements.
These statements are based on assumptions that may or may not prove to be accurate, and actual results may differ materially from those anticipated, due to a variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission.
Please consider such risks and uncertainties carefully in evaluating forward-looking statements and Palatin's prospects. Now I'd like to turn the call over to today's host, Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies. Sir, please go ahead.
Carl Spana - Palatin Technologies, Inc. - Co-Founder, President, CEO & Director
Thank you. Good morning, and welcome to the PL-9643 Phase II Dry Eye Disease Clinical Trial Results Call. I am Dr. Carl Spana. I'm CEO and
Palatin Technologies, Inc. - Special Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot